A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors Meeting Abstract
| Authors: | Cranmer, L.; Razak, A. A.; Ratan, R.; Choy, E.; George, S.; Liebner, D.; Stenehjem, D.; Gounder, M. |
| Abstract Title: | A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors |
| Meeting Title: | 113th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 82 |
| Issue: | 12 Suppl. |
| Meeting Dates: | 2022 Apr 8-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-06-15 |
| Language: | English |
| ACCESSION: | WOS:000892509502105 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.AM2022-CT185 |
| Notes: | Meeting Abstract: CT185 -- Source: Wos |
